ClinicalTrials.gg
CompletedNCT07691866Updated Oct 30, 2026

Effect of Chronotype on Balance and Cognitive Function

An observational study in Healhty, sponsored by Istanbul Gedik University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Istanbul Gedik University · Observational

How we know

Updated Oct 30, 2026Now CompletedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 35 Years
Sex
All
01

Study summary

Balance is the ability of an individual to maintain posture against gravity and sustain stability during movement; it depends on the coordinated functioning of the proprioceptive, visual, and vestibular systems, as well as the central nervous system. Current studies show that movement control occurs not only through the motor system but also through the interaction of sensory-cognitive-motor components. Cognitive functions encompass processes such as attention, memory, visuospatial skills, and executive functions, with attention and visuospatial processing playing a particularly important role in balance control. The literature reports significant relationships between balance and cognitive functions, particularly noting that increased attention requirements in dual-tasking situations negatively impact balance performance. Furthermore, it has been shown that both balance performance and cognitive functions are affected by circadian rhythm and chronotype, with individuals exhibiting different performance levels at different times of the day. Despite this, studies examining the relationship between balance and cognitive functions appear to have insufficiently addressed the chronotype factor. Therefore, the aim of this study is to investigate how the relationship between balance and cognitive functions changes according to individuals' chronotypes.

02

Conditions studied

  • Healhty
03

In context

Lead sponsor

Istanbul Gedik University is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healty young people

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being between 18-35 years old
  • Not using any neuropsychiatric medication
  • Not having undergone lower extremity surgery
  • Having at least a bachelor's degree

Exclusion criteria

Exclusion Criteria:

  • A history of a neurological disease
  • A history of a neuropsychiatric disease
  • Individuals with an intermediate type according to the Horne-Ostberg questionnaire results
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • Early type
  • Late type
06

What researchers measure

Primary outcomes

  1. Chronotype

    It will be assessed by survey (Horne Ostberg). The survey contains a total of 19 questions. Points will be added up based on participants' answers to obtain a score between 16 and 86. 16-30 will be considered evening type, and 70-86 will be considered morning type.

    Time frame: baseline - 2 weeks later

Secondary outcomes

  1. balance

    It will be assessed with KoreBalance balance system. Users will be asked to keep their eyes open while maintaining a center of gravity on an electronic device. Results are presented as point scores.

    Time frame: baseline - 2 weeks later

  2. Attention measurement

    It will be assessed with stroop test. Individuals will be tested at a desk. They will first be asked to read only the text written in three different colors. Then they will be asked to read the colors of the text. The total score will be recorded in milliseconds.

    Time frame: baseline - 2 weeks later

  3. Visuo-spatial attention

    It will be assessed with Flanker task. Eriksen Flanker Task is a classic cognitive psychology test that measures selective attention and response inhibition. You are asked to identify the direction of a central target (e.g., an arrow) while ignoring distracting "flanker" arrows on either side, which can either point the same way (congruent) or opposite (incongruent). The total correct responses are kept.

    Time frame: baseline - 2 weeks later

07

Study locations

1 site
  • Istanbul Gedik Uni
    Istanbul, Istanbul 34771, Turkey (Türkiye)
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2026 to primary completion in Sep 2026, 1 month.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jul 9, 2026
StartActual
Aug 1, 2026
Primary completionActual
Sep 25, 2026
CompletionActual
Oct 20, 2026was Sep 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 30, 2026
Study completion
Sep 26, 2026→Oct 20, 2026
Oct 14, 2026
Show all 2 updates
  1. Oct 30, 2026
    Recruiting→Completed
    + 3 other changes: date precision, site details and contact details
  2. Oct 14, 2026
    Study completion Sep 26, 2026→Oct 20, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07691866
Lead sponsor
Istanbul Gedik University
Responsible party
Yasin Yildirim (Assistant Proffessor, Istanbul Gedik University) — Principal investigator
First posted
Jul 9, 2026
Start date
Aug 1, 2026
Primary completion
Sep 25, 2026
Completion
Oct 20, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion